Symbols / ETON
ETON Chart
About
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 490.22M |
| Enterprise Value | 483.98M | Income | -6.68M | Sales | 70.32M |
| Book/sh | 0.86 | Cash/sh | 1.38 | Dividend Yield | — |
| Payout | 0.00% | Employees | 31 | IPO | — |
| P/E | — | Forward P/E | 18.10 | PEG | — |
| P/S | 6.97 | P/B | 21.21 | P/C | — |
| EV/EBITDA | 102.52 | EV/Sales | 6.88 | Quick Ratio | 1.14 |
| Current Ratio | 1.63 | Debt/Eq | 133.52 | LT Debt/Eq | — |
| EPS (ttm) | -0.26 | EPS next Y | 1.01 | EPS Growth | — |
| Revenue Growth | 117.50% | Earnings | 2026-03-17 | ROA | 1.26% |
| ROE | -34.17% | ROIC | — | Gross Margin | 56.59% |
| Oper. Margin | -0.17% | Profit Margin | -9.50% | Shs Outstand | 26.82M |
| Shs Float | 17.82M | Short Float | 7.82% | Short Ratio | 9.25 |
| Short Interest | — | 52W High | 23.00 | 52W Low | 11.09 |
| Beta | 1.22 | Avg Volume | 237.12K | Volume | 427.68K |
| Target Price | $30.00 | Recom | Strong_buy | Prev Close | $18.28 |
| Price | $18.28 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$30.00
Mean price target
2. Current target
$18.28
Latest analyst target
3. DCF / Fair value
$-0.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$18.28
Low
$26.00
High
$35.00
Mean
$30.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-05-29 | main | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-05-16 | reit | B. Riley Securities | Buy → Buy | $26 |
| 2025-05-14 | main | Craig-Hallum | Buy → Buy | $28 |
| 2025-03-19 | main | Craig-Hallum | Buy → Buy | $26 |
| 2025-03-19 | reit | B. Riley Securities | Buy → Buy | $24 |
| 2025-03-19 | reit | HC Wainwright & Co. | Buy → Buy | $33 |
| 2025-01-23 | main | HC Wainwright & Co. | Buy → Buy | $33 |
| 2025-01-10 | init | B. Riley Securities | — → Buy | $21 |
| 2025-01-08 | main | Craig-Hallum | Buy → Buy | $18 |
| 2025-01-06 | main | HC Wainwright & Co. | Buy → Buy | $17 |
| 2024-11-26 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-10-28 | main | Craig-Hallum | Buy → Buy | $15 |
| 2024-10-04 | main | Craig-Hallum | Buy → Buy | $10 |
| 2024-10-04 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-05-06 | init | Craig-Hallum | — → Buy | $8 |
| 2023-12-11 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-08-11 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-07-03 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-03-21 | reit | HC Wainwright & Co. | — → Buy | $10 |
- Eton Pharmaceuticals: An Undervalued Small Cap With High Growth (NASDAQ:ETON) - Seeking Alpha Fri, 23 Jan 2026 08
- Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th - GlobeNewswire Fri, 20 Feb 2026 11
- Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance hu, 06 Nov 2025 08
- Avoiding Lag: Real-Time Signals in (ETON) Movement - Stock Traders Daily hu, 19 Feb 2026 11
- February 2026's Top Growth Companies With Insider Influence - simplywall.st hu, 19 Feb 2026 17
- Eton Pharmaceuticals Licenses U.S. Marketing Rights for Ultra-Rare Disease Product Candidate, Anticipates FDA Approval by Mid-2026 - Quiver Quantitative Mon, 02 Feb 2026 08
- Implied Volatility Surging for Eton Pharmaceuticals Stock Options - Nasdaq hu, 04 Dec 2025 08
- Eton Pharmaceuticals stock rises after licensing ultra-rare disease drug - Investing.com Mon, 02 Feb 2026 08
- We Might See A Profit From Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Soon - Sahm Fri, 13 Feb 2026 08
- Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of "Hold" by Analysts - MarketBeat Wed, 11 Feb 2026 08
- How Low Can Eton Pharmaceuticals Stock Really Go? - Trefis Sun, 21 Dec 2025 08
- Eton Pharmaceuticals Has Focused Growth But Valuation Limits Upside: Why I Choose To Hold - Seeking Alpha Fri, 24 Oct 2025 07
- Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results - Yahoo Finance hu, 06 Nov 2025 08
- Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate - GlobeNewswire Mon, 02 Feb 2026 08
- Eton Pharmaceuticals: Growth At A Reasonable Price, Or Maybe Even Better With Options - Seeking Alpha Fri, 08 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 30000 | 132600 | — | Conversion of Exercise of derivative security at price 4.42 per share. | RIEDEL NORBERT G | Director | — | 2026-02-03 00:00:00 | D |
| 1 | 41713 | 673714 | — | Sale at price 16.02 - 16.16 per share. | GRUBER JAMES R | Chief Financial Officer | — | 2025-08-20 00:00:00 | D |
| 2 | 34000 | 504318 | — | Sale at price 14.73 - 14.92 per share. | KREMPA DAVID | Officer | — | 2025-06-16 00:00:00 | D |
| 3 | 7930 | 125484 | — | Purchase at price 15.82 per share. | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-10 00:00:00 | I |
| 4 | 210000 | 3592611 | — | Sale at price 16.81 - 19.02 per share. | BRYNJELSEN SEAN E | Chief Executive Officer | — | 2025-06-05 00:00:00 | D |
| 5 | 102400 | 373842 | — | Conversion of Exercise of derivative security at price 3.47 - 3.78 per share. | RIEDEL NORBERT G | Director | — | 2025-01-03 00:00:00 | D |
| 6 | 10000 | 79814 | — | Purchase at price 7.98 per share. | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-10-23 00:00:00 | I |
| 7 | 62070 | 434137 | — | Purchase at price 6.77 - 7.22 per share. | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-10-08 00:00:00 | I |
| 8 | 107500 | 504875 | — | Purchase at price 4.65 - 4.75 per share. | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-09-11 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -1.45M | -291.00K | -6.49M | -1.58M |
| TotalUnusualItems | 0.00 | 0.00 | 546.00K | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 0.00 | 546.00K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -3.82M | -936.00K | -9.02M | -1.96M |
| ReconciledDepreciation | 1.15M | 901.00K | 1.77M | 462.00K |
| ReconciledCostOfRevenue | 15.60M | 10.58M | 6.93M | 2.83M |
| EBITDA | -1.45M | -291.00K | -6.49M | -1.03M |
| EBIT | -2.60M | -1.19M | -8.26M | -1.50M |
| NetInterestIncome | -1.21M | 503.00K | -761.00K | -1.01M |
| NormalizedIncome | -3.82M | -936.00K | -9.02M | -2.50M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -3.82M | -936.00K | -9.02M | -1.96M |
| TotalExpenses | 41.61M | 32.83M | 29.51M | 23.33M |
| TotalOperatingIncomeAsReported | -2.60M | -1.19M | -8.26M | -1.50M |
| DilutedAverageShares | 25.89M | 25.64M | 25.15M | 25.21M |
| BasicAverageShares | 25.89M | 25.64M | 25.15M | 25.21M |
| DilutedEPS | -0.15 | -0.04 | -0.36 | -0.08 |
| BasicEPS | -0.15 | -0.04 | -0.36 | -0.08 |
| DilutedNIAvailtoComStockholders | -3.82M | -936.00K | -9.02M | -1.96M |
| NetIncomeCommonStockholders | -3.82M | -936.00K | -9.02M | -1.96M |
| NetIncome | -3.82M | -936.00K | -9.02M | -1.96M |
| NetIncomeIncludingNoncontrollingInterests | -3.82M | -936.00K | -9.02M | -1.96M |
| NetIncomeContinuousOperations | -3.82M | -936.00K | -9.02M | -1.96M |
| TaxProvision | 15.00K | 247.00K | 0.00 | 0.00 |
| PretaxIncome | -3.81M | -689.00K | -9.02M | -1.96M |
| OtherIncomeExpense | 546.00K | |||
| SpecialIncomeCharges | 0.00 | 0.00 | 546.00K | |
| GainOnSaleOfPPE | 0.00 | 0.00 | 181.00K | |
| OtherSpecialCharges | -365.00K | |||
| NetNonOperatingInterestIncomeExpense | -1.21M | 503.00K | -761.00K | -1.01M |
| TotalOtherFinanceCost | 1.21M | -503.00K | 761.00K | 1.01M |
| OperatingIncome | -2.60M | -1.19M | -8.26M | -1.50M |
| OperatingExpense | 26.01M | 22.25M | 22.58M | 20.50M |
| ResearchAndDevelopment | 3.25M | 3.32M | 4.00M | 6.24M |
| SellingGeneralAndAdministration | 22.75M | 18.93M | 18.58M | 14.27M |
| GeneralAndAdministrativeExpense | 22.75M | 18.93M | 18.58M | 14.27M |
| OtherGandA | 22.75M | 18.93M | 18.58M | 14.27M |
| GrossProfit | 23.41M | 21.06M | 14.32M | 19.00M |
| CostOfRevenue | 15.60M | 10.58M | 6.93M | 2.83M |
| TotalRevenue | 39.01M | 31.64M | 21.25M | 21.83M |
| OperatingRevenue | 39.01M | 31.64M | 21.25M | 21.83M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 26.71M | 25.69M | 25.35M | 24.63M |
| ShareIssued | 26.71M | 25.69M | 25.35M | 24.63M |
| NetDebt | 14.88M | |||
| TotalDebt | 29.92M | 5.40M | 6.52M | 6.70M |
| TangibleBookValue | -10.45M | 10.74M | 8.32M | 14.01M |
| InvestedCapital | 54.24M | 20.86M | 19.50M | 24.31M |
| WorkingCapital | 21.07M | 10.60M | 13.54M | 19.05M |
| NetTangibleAssets | -10.45M | 10.74M | 8.32M | 14.01M |
| CapitalLeaseObligations | 107.00K | 22.00K | 107.00K | 15.00K |
| CommonStockEquity | 24.43M | 15.48M | 13.08M | 17.63M |
| TotalCapitalization | 54.24M | 15.48M | 18.46M | 22.89M |
| TotalEquityGrossMinorityInterest | 24.43M | 15.48M | 13.08M | 17.63M |
| StockholdersEquity | 24.43M | 15.48M | 13.08M | 17.63M |
| RetainedEarnings | -107.89M | -104.07M | -103.13M | -94.11M |
| AdditionalPaidInCapital | 132.29M | 119.52M | 116.19M | 111.72M |
| CapitalStock | 27.00K | 26.00K | 25.00K | 25.00K |
| CommonStock | 27.00K | 26.00K | 25.00K | 25.00K |
| TotalLiabilitiesNetMinorityInterest | 51.70M | 16.26M | 11.95M | 9.84M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 31.75M | 22.00K | 5.49M | 5.28M |
| OtherNonCurrentLiabilities | 1.83M | |||
| LongTermDebtAndCapitalLeaseObligation | 29.92M | 22.00K | 5.49M | 5.28M |
| LongTermCapitalLeaseObligation | 107.00K | 22.00K | 107.00K | 15.00K |
| LongTermDebt | 29.81M | 5.38M | 5.26M | |
| CurrentLiabilities | 19.95M | 16.24M | 6.46M | 4.56M |
| CurrentDebtAndCapitalLeaseObligation | 5.38M | 1.03M | 1.42M | |
| CurrentDebt | 5.38M | 1.03M | 1.42M | |
| OtherCurrentBorrowings | 5.38M | 1.03M | 1.42M | |
| PayablesAndAccruedExpenses | 19.95M | 10.86M | 5.43M | 3.14M |
| CurrentAccruedExpenses | 15.78M | 9.01M | 3.66M | 1.37M |
| Payables | 4.17M | 1.85M | 1.77M | 1.77M |
| AccountsPayable | 4.17M | 1.85M | 1.77M | 1.77M |
| TotalAssets | 76.12M | 31.74M | 25.03M | 27.46M |
| TotalNonCurrentAssets | 35.10M | 4.90M | 5.03M | 3.86M |
| OtherNonCurrentAssets | 12.00K | 12.00K | 12.00K | 21.00K |
| GoodwillAndOtherIntangibleAssets | 34.88M | 4.74M | 4.75M | 3.62M |
| OtherIntangibleAssets | 4.75M | 3.62M | ||
| NetPPE | 209.00K | 150.00K | 260.00K | 219.00K |
| AccumulatedDepreciation | -446.00K | -395.00K | -352.00K | -351.00K |
| GrossPPE | 655.00K | 545.00K | 612.00K | 570.00K |
| Leases | 103.00K | 103.00K | 71.00K | 71.00K |
| ConstructionInProgress | 0.00 | 12.00K | 0.00 | |
| OtherProperties | 52.00K | 52.00K | 52.00K | 132.00K |
| MachineryFurnitureEquipment | 325.00K | 298.00K | 289.00K | 263.00K |
| BuildingsAndImprovements | 175.00K | 92.00K | 188.00K | 104.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 41.02M | 26.84M | 20.00M | 23.60M |
| OtherCurrentAssets | 5.49M | 1.13M | 1.29M | 3.18M |
| PrepaidAssets | 3.18M | |||
| Inventory | 15.23M | 911.00K | 557.00K | 550.00K |
| Receivables | 5.36M | 3.41M | 1.85M | 5.47M |
| AccountsReceivable | 5.36M | 3.41M | 1.85M | 5.47M |
| AllowanceForDoubtfulAccountsReceivable | -238.00K | -129.00K | -262.00K | -96.00K |
| GrossAccountsReceivable | 5.60M | 3.54M | 2.11M | 5.57M |
| CashCashEquivalentsAndShortTermInvestments | 14.94M | 21.39M | 16.30M | 14.41M |
| CashAndCashEquivalents | 14.94M | 21.39M | 16.30M | 14.41M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -9.04M | 6.04M | 2.03M | -7.98M |
| RepaymentOfDebt | -1.16M | -1.16M | -385.00K | -150.00K |
| IssuanceOfDebt | 25.31M | 0.00 | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 7.00M | 0.00 | 0.00 | 0.00 |
| CapitalExpenditure | -10.01M | -775.00K | -2.79M | -3.26M |
| InterestPaidSupplementalData | 665.00K | 842.00K | 730.00K | 815.00K |
| IncomeTaxPaidSupplementalData | 82.00K | 247.00K | 0.00 | 0.00 |
| EndCashPosition | 14.94M | 21.39M | 16.30M | 14.41M |
| BeginningCashPosition | 21.39M | 16.30M | 14.41M | 21.30M |
| ChangesInCash | -6.45M | 5.08M | 1.90M | -6.89M |
| FinancingCashFlow | 32.59M | -957.00K | -134.00K | 391.00K |
| CashFlowFromContinuingFinancingActivities | 32.59M | -957.00K | -134.00K | 391.00K |
| NetOtherFinancingCharges | -180.00K | |||
| ProceedsFromStockOptionExercised | 1.44M | 378.00K | 251.00K | 541.00K |
| NetCommonStockIssuance | 7.00M | 0.00 | 0.00 | 0.00 |
| CommonStockIssuance | 7.00M | 0.00 | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | 24.15M | -1.16M | -385.00K | -150.00K |
| NetLongTermDebtIssuance | 24.15M | -1.16M | -385.00K | -150.00K |
| LongTermDebtPayments | -1.16M | -1.16M | -385.00K | -150.00K |
| LongTermDebtIssuance | 25.31M | 0.00 | 0.00 | 0.00 |
| InvestingCashFlow | -40.01M | -775.00K | -2.79M | -2.56M |
| CashFlowFromContinuingInvestingActivities | -40.01M | -775.00K | -2.79M | -2.56M |
| NetBusinessPurchaseAndSale | -30.00M | 0.00 | 0.00 | |
| PurchaseOfBusiness | -30.00M | 0.00 | 0.00 | |
| NetIntangiblesPurchaseAndSale | -9.99M | -775.00K | -2.75M | -3.25M |
| PurchaseOfIntangibles | -9.99M | -775.00K | -2.75M | -3.25M |
| NetPPEPurchaseAndSale | -26.00K | 0.00 | -38.00K | 691.00K |
| SaleOfPPE | 0.00 | 0.00 | 700.00K | |
| PurchaseOfPPE | -26.00K | 0.00 | -38.00K | -9.00K |
| OperatingCashFlow | 969.00K | 6.82M | 4.82M | -4.72M |
| CashFlowFromContinuingOperatingActivities | 969.00K | 6.82M | 4.82M | -4.72M |
| ChangeInWorkingCapital | -698.00K | 3.53M | 7.66M | -6.21M |
| ChangeInOtherWorkingCapital | 38.00K | |||
| ChangeInPayablesAndAccruedExpense | 7.04M | 5.35M | 2.21M | -454.00K |
| ChangeInAccruedExpense | 4.72M | 5.29M | 2.22M | 116.00K |
| ChangeInPayable | 2.32M | 53.00K | -8.00K | -570.00K |
| ChangeInAccountPayable | 2.32M | 53.00K | -8.00K | -570.00K |
| ChangeInPrepaidAssets | -3.35M | 94.00K | 1.84M | -1.03M |
| ChangeInInventory | -1.31M | -354.00K | -7.00K | 692.00K |
| ChangeInReceivables | -3.12M | -1.56M | 3.62M | -5.42M |
| ChangesInAccountReceivables | -3.12M | -1.56M | 3.62M | -5.42M |
| OtherNonCashItems | 1.18M | 184.00K | 189.00K | 148.00K |
| StockBasedCompensation | 3.17M | 3.14M | 4.22M | 3.38M |
| DepreciationAmortizationDepletion | 1.15M | 901.00K | 1.77M | 462.00K |
| DepreciationAndAmortization | 1.15M | 901.00K | 1.77M | 462.00K |
| OperatingGainsLosses | -546.00K | |||
| GainLossOnSaleOfPPE | 0.00 | 0.00 | -181.00K | |
| NetIncomeFromContinuingOperations | -3.82M | -936.00K | -9.02M | -1.96M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ETON
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|